Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro

Brain Research Bulletin

Volumn 44, Issue 5, 1997, Pages 603-610

  Kombian, Samuel B ^a   Saleh, Tarek M ^a,e   Fiagbe, N I Yao ^b   Chen, Xihua ^a   Akabutu, John J ^c   Buolamwini, John K ^d   Pittman, Quentin J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

Author keywords

Addiction; Dopamine; EPSC; Hallucinogen; Nystatin patch recording

Indexed keywords

ALKALOID; IBOGAINE; PLANT EXTRACT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG ACTIVITY; DRUG DEPENDENCE; NERVE EXCITABILITY; NONHUMAN; PARABRACHIAL NUCLEUS; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; WITHDRAWAL SYNDROME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; IBOGAINE; NEURONS; PATCH-CLAMP TECHNIQUES; PLANT EXTRACTS; PONS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION; TIME FACTORS;

EID: 0030867099     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(97)00284-0     Document Type: Article

References (50)

1. Battersby R. T., Brown R. T., Kapil R. S., Plunkett A. O., Taylor J. B. Biosynthesis of indole alkaloids. Chem. Commun. 2:1966;46-47.
2. Benwell M. E., Holtom P. E., Moran R. J., Balfour D. J. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br. J. Pharmacol. 117:1996;743-749.
3. Bowen W. D., Vilner B. J., Williams W., Bertha C. M., Kuehne M. E., Jacobson A. E. Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. Eur. J. Pharmacol. 279:1995;R1-R3.
4. Cappendijk S. L., Fekkes D., Dzoljic M.R. The inhibitory effect of norharman on morphine withdrawal syndrome in rats Comparison with ibogaine . Behav. Brain Res. 65:1994;117-119.
5. Chen K., Kokate T. G., Donevan S. D., Carroll F. I., Rogawski M. A. Ibogaine block of the NMDA receptor In vitro and in vivo studies . Neuropharmacology. 35:1996;423-431.
6. Codd E. E. High affinity ibogaine binding to a mu opioid agonist site. Life Sci. 57:1995;L315-PL320.
7. Deecher D. C., Teitler M., Soderlund D.M., Bornmann W. G., Kuehne M. E., Glick S. D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 571:1992;242-247.
8. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
9. Dzoljic E. D., Kaplan C. D., Dzoljic M. R. Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. Arch. Int. Pharmacodyn. Ther. 294:1988;64-70.
10. Fiagbe N. I. Y. Proposals for investigation of Voacanga africana (Apocynaceae) An anti-addictive drug? 11th Pharmaceut . Technol. Conf. 1:1992;334-338.
11. French E. D., Dillon K., Ali S. F. Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons. Life Sci. 59:1996;L199-PL205.
12. Glick S. D., Gallagher C. A., Hough L. B., Rossman K. L., Maisonneuve I. M. Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine. Brain Res. 588:1992;173-176.
13. Glick S. D., Rossman K., Rao N. C., Maisonneuve I. M., Carlson J. N. Effects of ibogaine on acute signs of morphine withdrawal in rats Independence from tremor . Neuropharmacology. 31:1992;497-500.
14. Harsing L. G. Jr, Sershen H., Lajtha A. Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum. J. Neural Transm. [Gen. Sect.]. 96:1994;215-225.
15. 1 receptor activation. J. Physiol. (Lond.). 492:1996;143-154.
16. Hedreen J. Terminal degeneration demonstrated by the Fink-Heimer method following lateral ventricular injection of 6-hydroxydopamine. Brain Res. Bull. 5:1980;425-436.
17. Kesner R. P., Jackson-Smith P., Henry C., Amann K. Effects of ibogaine on sensory-motor function, activity, and spatial learning in rats. Pharmacol. Biochem. Behav. 51:1995;103-109.
18. B receptors presynaptically modulate excitatory synaptic transmission in the rat supraoptic nucleus in vitro. J. Neurophysiol. 76:1996;1166-1179.
19. Mach R. H., Smith C. R., Childers S. R. Ibogaine possesses a selective affinity for sigma 2 receptors. Life Sci. 57:1995;L57-PL62.
20. Maisonneuve I. M., Glick S. D. Interactions between ibogaine and cocaine in rats In vivo microdialysis and motor behavior . Eur. J. Pharmacol. 212:1992;263-266.
21. Maisonneuve I. M., Keller R. W. Jr, Glick S. D. Interactions of ibogaine and D-amphetamine In vivo microdialysis and motor behavior in rats . Brain Res. 579:1992;87-92.
22. Maisonneuve I. M., Rossman K. L., Keller R. W. Jr, Glick S. D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 575:1992;69-73.
23. Mash D. C., Staley J. K., Baumann M. H., Rothman R. B., Hearn W. L. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 57:1995;L45-PL50.
24. Mash D. C., Staley J. K., Pablo J.P., Holohean A. M., Hackman J. C., Davidoff R. A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
25. Naranjo C. Psychotherapeutic possibilities of new fantasy-enhancing drugs. Clin. Toxicol. 2:1973;209-224.
26. Nicola S. M., Kombian S. B., Malenka R. C. Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors. J. Neurosci. 16:1996;1591-1604.
27. Pearl S. M., Herrick-Davis K., Teitler M., Glick S. D. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res. 675:1995;342-344.
28. Popik P. Facilitation of memory retrieval by the "anti-addictive" alkaloid, ibogaine. Life Sci. 59:1996;L379-L384.
29. Popik P., Layer R. T., Fossom L. H., Benveniste M., Geter-Douglass B., Witkin J. M., Skolnick P. NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:1995;753-760.
30. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology (Berlin). 114:1994;672-674.
31. Popik P., Layer R. T., Skolnick P. 100 years of ibogaine Neurochemical and pharmacological actions of a putative anti-addictive drug . Pharmacol. Rev. 47:1995;235-253.
32. Rezvani A. H., Overstreet D. H., Lee Y. W. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol. Biochem. Behav. 52:1995;615-620.
33. Saleh T. M., Cechetto D. F. Neurotransmitters in the parabrachial nucleus mediating visceral input to the thalamus in rats. Am. J. Physiol. 266:1994;R1287-R1296.
34. Saleh T. M., Cechetto D. F. Neurochemical interactions in the parabrachial nucleus mediating visceral inputs to visceral thalamic neurons. Am. J. Physiol. 268:1995;R786-R795.
35. Saleh T. M., Kombian S. B., Zidichouski J. A., Pittman Q. J. Peptidergic modulation of synaptic transmission in the parabrachial nucleus in vitro Importance of degradative enzymes in regulating synaptic efficacy . J. Neurosci. 16:1996;6046-6055.
36. Schneider J. A., Sigg E. B. Neuropharmacological studies of ibogaine, an indole alkaloid with central stimulant properties. Ann. NY Acad. Sci. 66:1957;765-776.
37. Sershen H., Harsing L. G. Jr, Hashim A., Lajtha A. Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats. Life Sci. 51:1992;1003-1011.
38. Sershen H., Hashim A., Lajtha A. Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats. Neurochem. Res. 19:1994;1463-1466.
39. 3H] serotonin from mouse striatum. Pharmacol. Biochem. Behav. 53:1996;863-869.
40. Sershen H., Hashim A., Lajtha A. Ibogaine and cocaine abuse Pharmacological interactions at dopamine and serotonin receptors . Brain Res. Bull. 42:1997;161-168.
41. Sharpe L. G., Jaffe J. H. Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat. NeuroReport. 1:1990;17-19.
42. Sheppard S. G. A preliminary investigation of ibogaine Case reports and recommendations for further study . J. Subst. Abuse Treat. 11:1994;379-385.
43. Thomas D. W., Bieman K. Alkaloids of Voacanga africana. Lloydia. 31:1968;1-8.
44. Thomas R. A possible biosynthetic relationship between the cyclopentanoid monoterpenes and the indole alkaloids. Tetrahedron Lett. 16:1961;544-553.
45. Vincent D., Sero M. Action inhibitrice de Tabernanthe iboga sur la cholinesterase du serum. C. R. S. Soc. Biol. 136:1942;612-614.
46. Whitaker P. M., Seeman P. Hallucinogenic binding to dopamine/neuroleptic receptors. J. Pharm. Pharmacol. 29:1977;506-507.
47. Wise R. A., Bozarth M. A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94:1987;469-492.
48. Yamasaki M., Leete E. Biosynthesis of the iboga alkaloids The incorporation of tryptophan-3C14 into ibogaine . Tetrahedron Lett. 23:1964;1499-1501.
49. Zidichouski J. A., Easaw J. C., Jhamandas J. H. Glutamate receptor subtypes mediate excitatory synaptic responses of rat lateral parabrachial neurons. Am. J. Physiol. 270:1996;H1557-H1567.
50. Zidichouski, J. A.; Jhamandas, J. H. Electrophysiological characterization of excitatory amino acid responses in the rat lateral parabrachial neurons in vitro. Brain Res. 611:313-321; 1993.